Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium

Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series

“…These results are in line with previous observations. 13 , 14 , 15 , 16 , 17 Moreover, the 30-day hospitalization rate after monoclonal antibody infusion in our cohort seems lower than those reported in two recent case-series (8.7% and 15%, respectively 24 , 25 ).…”

“…Unfortunately, kidney transplant recipients were excluded from the studies. Nevertheless, we and others 13 , 14 , 15 , 16 , 17 have reported case-series suggesting that neutralizing monoclonal antibody therapy may be used safely in kidney transplant recipients with mild forms of COVID-19. However, concerns were recently raised regarding the efficacy of monoclonal antibody therapy in patients infected with the B.1.1.529 (Omicron) variant SARS-CoV-2.…”

Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience

“…Our results confirm the activity and safety of monoclonal antibody therapy demonstrated in other real-life series. 3 , 4 However, to our best knowledge, ours is the first report focusing on Sotrovimab-favorable tolerability and efficacy profile in transplant patients, a very interesting clinical finding considering its preserved activity against Omicron variant.…”

“…Nevertheless, real world data regarding the use of monoclonal antibodies in these patients are scarce 2 and are limited to few case series based on Casirivimab/Imdevimab or Bamlanivimab/Etesevimab administration. 3 , 4 No published study evaluated efficacy and safety of Sotrovimab in this setting so far.…”

Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients

“…The FDA issued an EUA for Regeneron for mild to moderate COVID-19 at high risk of progression in February 2021 [ 69 ]. In a study of 12 kidney transplant recipients, in patients with mild COVID-19 disease, casirivimab/imdevimab resulted in rapid resolution of symptoms and no one required repeat hospitalization [ 70 ]. With the latest Omicron variant wave, Regeneron is no longer recommended as it is ineffective against this variant [ 7 ••, 71 ].…”